Phase I Study of TST10088 to be Presented at 20th EORTC-NCI-AACR Symposium

October 2, 2008 02:56 PM

NORTH VANCOUVER, BC, Canada, October 2, 2008 - Investigators at the Princess Margaret Hospital, University of Colorado Cancer Center & BC Cancer Agency will present "Phase I study of the ribosome inactivating protein prodrug TST10088 (TST88) in patients with advanced solid tumors" on 23 October 2008 at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics", Geneva, Switzerland (21 - 24 October 2008).